Table 1.
Patient and Treatment Characteristics
| No. of Patients (% or range) | ||||
|---|---|---|---|---|
| All Patients (n=35) |
Patients with Aortic Toxicity (n=2) |
|||
| Age, years, median (range) | 63 (38–73) | 68 (66–70) | ||
| Sex | ||||
| Male | 17 (49%) | 1 (50%) | ||
| Female | 18 (51%) | 1 (50%) | ||
| Hypertension | ||||
| Yes (blood pressure ≥140/90) | 11 (31%) | 0 | ||
| No (<140/90) | 24 (69%) | 2 (100%) | ||
| Preexisting CV abnormalities | 8 (23%) | 2 (100%) | ||
| Abdominal aortic aneurysm | 2 (6%) | |||
| Aortic valce replacement | 1 (3%) | |||
| Cardiac arrythmias* | 2 (6%) | 1 (50%) | ||
| Coronary artery disease | 3 (9%) | 1 (50%) | ||
| Anticoagulation therapy | 12 (34%) | 2 (100%) | ||
| Aspirin | 15 (14%) | |||
| Clopidogrel and aspirin | 2 (6%) | 1 (50%) | ||
| Warfarin | 3 (9%) | 1 (50%) | ||
| Hyperlipidemia | ||||
| Yes | 4 (11%) | 1 (50%) | ||
| No | 31 (89%) | 1 (50%) | ||
| Diabetes | ||||
| Yes | 4 (11%) | 1 (50%) | ||
| No | 31 (89%) | 1 (50%) | ||
| Vital status at analysis | ||||
| Alive | 11 (31%) | |||
| Dead | 24 (69%) | 2 (100%) | ||
| Cause of death | ||||
| Aortic rupture | 2 (6%) | 2 (100%) | ||
| Cardiac | 3 (9%) | |||
| Pulmonary | 4 (11%) | |||
| Infection | 1 (3%) | |||
| Cancer-related | 10 (29%) | |||
| Unknown | 4 (11%) | |||
| Follow-up interval, median (range) | ||||
| All patients | 17 mo (2–70 mo) | |||
| Patients alive at analysis | 42 mo (14–70 mo) | |||
| Patients dead at analysis | 12 mo (2–45 mo) | 24 mo (21–64 mo) | ||
| 1st Trtmt | 2nd Trmt | 1st Trtmt | 2nd Trtmt | |
| Concurrent chemotherapy | ||||
| Yes | 24 (69%) | 21 (60%) | 1 (50%) | 1 (50%) |
| No | 11 (31%) | 14 (40%) | 1 (50% | 1 (50%) |
| Prescribed dose, Gy median (range) | 54 (45–70) | 60 (30–70) | 55.4 (50.4–60.4) | 64.5 (63–66) |
| Fraction size, Gy median (range) | 1.8 (1.2–3.0) | 2.0 (1.5–3.0) | 1.8 | 1.9 (1.8–2.0) |
| No. of Fractions median (range) | 30 (15–58) | 30 (10–42) | 31 (28–33) | 34 (33–35) |
| Max dose to 1 cm3 of aorta, median (range) | ||||
| Raw dose, Gy | 56.0 (25.5–76.2) | 49.9 (3.5–74.3) | 55.0 (51.0–59.0) | 68.5 (68.0–69.0) |
| Composite raw dose, Gy | 110.0 (74.5–142.7) | 123.5 (120.0–127.0) | ||
| NIDR | 23.9 (7.0–37.5) | 53.8 (2.2–79.3) | 21.2 (20.6–21.7) | 71.6 (70.0–73.2) |
| Composite NIDR | 73.6 (38.6–99.4) | 92.8 (90.6–94.9) | ||
| Duration of radiation therapy, median (range) | 39 d (14–52 d) | 38 d (14–53d) | 46 d (40–52 d) | 44 d (39–48 d) |
| Interval to re-treatment, median (range) | 30 mo (1–185 mo) | 43 mo (21–64 mo) | ||
Abbreviations: NIDR, dose normalized for fraction size and adjusted for tissue recovery between trtmts
*
Atrial fibrillation and premature ventricular contractions